A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Tamibarotene
DRUG: Azacitidine
DRUG: Daratumumab

Sponsor

Syros Pharmaceuticals